Recombinant factor XIII prophylaxis is safe and effective in young children with congenital factor XIII‐A deficiency: international phase 3b trial results
B. A. Kerlin; A. Inbal; A. Will; M. Williams; M.‐L. Garly; L. Jacobsen; S. L. Kearney
Author Information: Nationwide Children's Hospital and The Ohio State University College of Medicine
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.